טוען...
Oral anticoagulation is preferable to injected, but only if it is safe and effective: An interview study of patient and carer experience of oral and injected anticoagulant therapy for cancer-associated thrombosis in the select-d trial
BACKGROUND: Cancer patients have a four- to fivefold greater risk of thrombosis than the general population. Recommended treatment for cancer-associated thrombosis is 3–6 months of low-molecular-weight heparin. The ‘select-d’ trial is an open-label, randomised, multi-centre pilot trial in patients w...
שמור ב:
| הוצא לאור ב: | Palliat Med |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
SAGE Publications
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6506899/ https://ncbi.nlm.nih.gov/pubmed/30488789 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0269216318815377 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|